Clinical trialPhase 1Recruiting
First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer
A Phase 1, Open-Label, Dose-Escalation and Expansion Study of SNV1521 in Combination With RAS Inhibition in Participants With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
- Outcome
- Ongoing
- Phase
- Phase 1
- Status
- Recruiting
- Study type
- Interventional
- Start
- 1 September 2026
- Expected end
- 1 June 2029
- Enrollment
- 40 participants
- Sites
- 1
- Primary outcomes
- Safety and tolerability of SNV1521 plus daraxonrasib: treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities
- Sponsor
- Industry
- Results posted
- No
- Last update
- 27 October 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try